No Data
No Data
MicroStrategy Was The Best Among These 10 Large-Cap Stocks Scoring Big Last Week (May 12-May 19, 2024): Are They In Your Portfolio?
These large-cap stocks were the best performers in the last week. Are they in your portfolio?MicroStrategy Incorporated (NASDAQ:MSTR) shares increased 30.10% following a rise in the price of Bitcoin.M
Form 144 | Alcon(ALC.US) Officer Proposes to Sell 198.5K in Common Stocks
SEC FILLINGS DISCLOSED/ May 17, $Alcon(ALC.US)$ Officer Duplan Sergio intends to sell 2,250 shares of its common stock on May 17, with a total market value of approximately $198.5K. Duplan Sergio ha
Moody's Upgrades Alcon on Strong Financial Performance
Moody's on Friday upgraded Alcon's (ALC.SW) long-term issuer rating to Baa1 from Baa2, mainly driven by the Swiss eye care products company's continued strong financial performance. The rating agency
C-MER Eye Care Sells Stake in Israel-Based Belkin Vision to Alcon
A unit of C-MER Eye Care Holdings (HKG:3309) sold its equity interests in Belkin Vision, maker of the Eagle laser for glaucoma, to Swiss eye care giant Alcon Pharmaceuticals, according to a Thursday f
Hima Ophthalmology subsidiary has sold its shares in Belkin Vision Ltd., to Alcon
Hima Ophthalmology (03309) announced that Hong Kong (International) Eye Care Group Co., Ltd. (Hong Kong Ophthalmology), a wholly-owned subsidiary of the company, has sold it to Belkin Vision Ltd. (Sale Company) shares are vested in Alcon Pharmaceuticals Ltd (Alcon). Its book value as at 31 December 2023 was HK$23.3 million, and classified as a financial asset that includes other full income at fair value. The costs are as follows: the fixed cash cost at completion is approximately US$6.4 million; and possibly the cost does not exceed US$17 million,
Hima Ophthalmology (03309.HK) has sold shares in Belkin Vision Ltd., to Alcon
On May 16, GLONGHUI (03309.HK) announced that Hong Kong (International) Ophthalmology Group Co., Ltd., a wholly-owned subsidiary of the company, has sold its shares in Belkin Vision Ltd. (the selling company) to Alcon Pharmaceuticals Ltd (Alcon). Its book value as of 31 December 2023 was HK$23.3 million, and classified as a financial asset that includes other full income at fair values. The costs are as follows: the fixed cash cost at completion is approximately $6.4 million; and the likely cost is not more than $17.0 million
No Data